Case Reports
doi: 10.1002/ccr3.686.
eCollection 2016 Oct.
Acute cardiac decompensation in a patient with beta-thalassemia and diabetes mellitus following cessation of chelation therapy
Affiliations
- PMID: 27761254
- PMCID: PMC5054478
- DOI: 10.1002/ccr3.686
Item in Clipboard
Case Reports
Acute cardiac decompensation in a patient with beta-thalassemia and diabetes mellitus following cessation of chelation therapy
Clin Case Rep.
.
Abstract
Patients with higher liver iron stores are likely to have a worse cardiac outcome following noncompliance with chelation. Cardiovascular magnetic resonance identifies myocardial siderosis allowing optimization of iron chelation regimes. Diabetes puts thalassemic patients at increased risk of myocardial fibrosis. Dual chelation therapy with deferoxamine and deferiprone offers improved cardiac outcomes.
Keywords: Beta‐thalassemia major; chelation; diabetes; heart failure.
Figures
Bilateral pleural effusions are demonstrated on axial view of thoracic MRI .
Hepatic ferriscan on presentation.
Similar articles
-
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.Circulation. 2007 Apr 10;115(14):1876-84. doi: 10.1161/CIRCULATIONAHA.106.648790. Epub 2007 Mar 19. Circulation. 2007. PMID: 17372174 Clinical Trial.
-
comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major.Int J Hematol. 2007 Dec;86(5):385-9. doi: 10.1007/BF02983992. Int J Hematol. 2007. PMID: 18192103
-
Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.Hemoglobin. 2009;33(5):312-22. doi: 10.3109/03630260903213231. Hemoglobin. 2009. PMID: 19814677
-
Thalassemia.Hematology Am Soc Hematol Educ Program. 2004:14-34. doi: 10.1182/asheducation-2004.1.14. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561674 Review.
-
The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.Am J Hematol. 2018 Jul;93(7):943-952. doi: 10.1002/ajh.25103. Epub 2018 Apr 28. Am J Hematol. 2018. PMID: 29635754
Cited by
-
Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter.Ther Adv Endocrinol Metab. 2018 Apr 6;9(8):259-268. doi: 10.1177/2042018818767220. eCollection 2018. Ther Adv Endocrinol Metab. 2018. PMID: 30181852 Free PMC article. Review.
References
-
- Rund, D. , and Rachmilewitz E.. 2005. Beta‐thalassemia. N. Engl. J. Med. 353:1135–1146. - PubMed
-
- Pennell, D. J. , Udelson J. E., Arai A. E., Bozkurt B., Cohen A. R., Galanello R., et al. 2013. Cardiovascular function and treatment in beta‐thalassemia major: a consensus statement from the American Heart Association. Circulation 128:281–308. - PubMed
-
- Toumba, M. , Sergis A., Kanaris C., and Skordis N.. 2007. Endocrine complications in patients with thalassaemia major. Pediatr. Endocrinol. Rev. 5:642–648. - PubMed
-
- Pepe, A. , Meloni A., Rossi G., Caruso V., Cuccia L., Spasiano A., et al. 2013. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study. Br. J. Haematol. 163:520–527. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
